article thumbnail

SPECIAL REPORT: 2019 Biopharma Outlook – Facing an Uncertain Future

Xconomy

In this Xconomy Special Report, our veteran biotech journalists Alex Lash and Ben Fidler bring you deep insights, based on conversations with key industry leaders, on what 2019 and beyond hold for biopharmaceutical companies. In this Report, you’ll learn: The key indicators that suggest a possible downturn is on the way.

Report 83
article thumbnail

SPECIAL REPORT: 2019 Blockchain Outlook — Reality Check

Xconomy

In this Xconomy Special Report , our veteran technology journalists Bernadette Tansey, David Holley, and I bring you deep insights from key industry leaders and observers about what the future holds for.

Report 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Report: IPO Activity Picking Back Up Following Quiet, Volatile Q3

Xconomy

While the headlines may be dominated by news of WeWork putting its IPO on hold after reports about its questionable corporate governance, the overall initial public offering market is doing just fine. The total for the first three quarters of 2019 was about $8 billion shy of.

article thumbnail

AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results

Xconomy

[ Editor’s note: Alex Lash co-authored this report ] The American Association for Cancer Research’s annual meeting is wrapping up in Atlanta today. But AACR has its fair share of notable news, events, and reports. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

article thumbnail

Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup

Xconomy

The company reported revenues of about $120.3 million in 2019. San Diego-based Ligand (NASDAQ: LGND ) generates revenue from licensing deals and royalties paid by pharmaceutical companies that use technologies it develops or acquires for their own drug research. He likened the.

article thumbnail

Monzo: What do you need to know?

Tech.Co

In June 2019, banking start-up Monzo announced its plans to launch in the US. With a community forum, along with its aims to offer easily accessible and readable annual reports (you can view reports for 2017, 2018 and 2019 on its site), Monzo champions transparency. But what is Monzo, exactly? million users.

Summary 114
article thumbnail

15 For ’19: Key Clinical Data to Watch For Next Year (Part 2)

Xconomy

Editor’s note: Alex Lash, Corie Lok, and Frank Vinluan contributed to these reports. Disease area : Nonalcoholic steatohepatitis (NASH) Companies : Intercept Pharmaceuticals, Genfit Trial : REGENERATE , RESOLVE-IT Data expected : 1H 2019 (REGENERATE), 2H 2019 (RESOLVE-IT) Why We’re Watching : Sometimes diseases are.

Study 83